NASDAQ · IMVT
Immunovant, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMVT: Nov 09, 2026
Immunovant, Inc. Common Stock is expected to report earnings on 11/09/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.73. The reported EPS for the same quarter last year was $-0.73.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.73 | $-0.63 | $-0.79 | 6 |
| Dec 2026 | $-0.72 | $-0.62 | $-0.80 | 5 |
| Mar 2027 | $-0.73 | $-0.59 | $-0.83 | 5 |
| Jun 2027 | $-0.70 | $-0.61 | $-0.79 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool · MarketBeat- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- Zacks · Sep 24, 11:50 AM EDTIMVT Ends Cutaneous Lupus Erythematosus Program, Stock DownImmunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
- RTTNews · Sep 23, 7:25 AM EDTImmunovant To Stop Development Of IMVT-1402 In Cutaneous Lupus Erythematosus(RTTNews) – Immunovant (IMVT) announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 or imeroprubart for the treatment of cutaneous lupus erythematosus. The study did not achieve statistical significance on its primary endpoint of percent chang
- The Motley Fool · Aug 13, 8:01 AM EDTImmunovant (IMVT) Q1 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 3:04 PM EDTImmunovant Q1 Earnings Call HighlightsRoivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Exe
- Zacks · Aug 6, 11:22 AM EDTImmunovant's Q1 Loss Wider Than Expected, Pipeline in ProgressIMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
- Zacks · Jun 19, 11:30 AM EDTImmunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Jun 12, 10:08 AM EDTImmunovant Stock Gains 12.4% in a Month: What's Driving It?IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
- Zacks · May 21, 9:19 AM EDTIMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study DataImmunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
- RTTNews · May 20, 10:19 PM EDTSLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX(RTTNews) – In today's gainers' list, we cover HCW Biologics, its upcoming catalysts and going concern risks; Silexion's development progress of its lead drug candidate SIL204; Immunovant's encouraging rheumatoid arthritis data; why investors will be closely watching Black Diamon
- BNK Invest · May 20, 4:16 PM EDTNoteworthy Wednesday Option Activity: IMVT, TE, HDAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Immunovant Inc (Symbol: IMVT), where a total of 13,829 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 97.9
- MarketBeat · May 20, 10:07 AM EDTImmunovant Q4 Earnings Call HighlightsRoivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the com
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Immunovant, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.